HZNM yields 1000000.00% · ABBV yields 3.06%● Live data
📍 HZNM pulled ahead of the other in Year 1
Combined, HZNM + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HZNM + ABBV for your $10,000?
Horizon Minerals Corp. engages in the exploration and development of mineral properties in the United States. It primarily focuses on exploring for lithium deposits. The company has interests in the SFE Property, a section of Scotty's Southeast Claims with 312 twenty-acre unpatented mining claims located in Central Nye County, Nevada; the Crystal Basin Claims covering 245 twenty-acre unpatented mining claims situated in Southern Nye County, Nevada; the Cholla Claims with 424 unpatented twenty-acre claims located in eastern San Bernardino County, California; and the North Lobe Claims covering 160 unpatented twenty-acre claims situated in Elko County, northeastern Nevada. It also has interest in 224 claim units totaling 4,480 acres located in Toole County, Utah. The company was formerly known as Safe Dynamics Corp. and changed its name to Horizon Minerals Corp. in March 2013. Horizon Minerals Corp. was founded in 2011 and is headquartered in Las Vegas, Nevada.
Full HZNM Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.